Answer
Denosumab inhibits osteoclast formation, function and survival by preventing the RANKL/RANK interaction, thereby decreasing bone resorption in cortical and trabecular bone.
Sources for this answer
- Prolia 60 mg solution for injection in pre-filled syringeAmgen Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 38Document updated
Sources checked